AUS
NZ
UK
CA
USA
IND
Healt
Orthocell (ASX:OCC) Expands US Remplir Launch Strategically
October 17, 2025 11:34 AM AEDT| By SamOrthocell strengthens US expansion of Remplir through a major placement, boosting its regenerative medicine pipeline and global commercialisation strategy.
TrivarX Expands Early Brain Cancer Detection with Stabl-Im
October 16, 2025 01:39 PM AEDT| By SamTrivarX (ASX:TRI) advances brain cancer diagnostics with Stabl-Im acquisition, offering non-invasive MRI-based detection and strengthening its position in neurological and oncology markets.
Ansell (ASX:ANN) Performance: Key Investor Insights
October 16, 2025 11:15 AM AEDT| By SamAn in-depth analysis of Ansell (ASX:ANN) focusing on return on capital employed, reinvestment trends, and implications for investors in the ASX market.
Cochlear (ASX:COH) Shares: 6 Must-Know Investor Metrics
October 15, 2025 05:44 PM AEDT| By SamExplore Cochlear Ltd (ASX:COH) shares with key metrics, revenue trends, profitability, and financial health insights for investors in the ASX stock market and ASX200 index.
Biotron (ASX:BIT) Strengthens Pipeline with Sedarex Acquisition and Capital Raising
October 15, 2025 04:06 PM AEDT| By SamBiotron (ASX:BIT) acquires Sedarex, a next-gen anaesthetic, backed by a capital raising to advance development and diversify its clinical pipeline in the ASX stock market.
Biotech Momentum on the ASX: Nexsen’s Dynamic Debut and Sector Revival
October 14, 2025 02:33 PM AEDT| By SamNexsen (ASX:NXN) energises the ASX biotech scene with innovative diagnostics, joined by Tetratherix, Clarity Pharmaceuticals, and Audeara driving breakthroughs across healthcare, imaging, and hearing technology in Australia’s dynamic life sciences se...
Ramsay Health Care’s Struggles Reflect Deeper Industry Pressures in ASX 200
October 10, 2025 05:45 PM AEDT| By SamAGM season heats up for Australian investors as top ASX ordinaries stocks prepare for updates. Companies like (ASX:ABB) are expected to draw strong market attention amid upbeat ASX 200 sentiment.
Can Sigma Healthcare (ASX:SIG) Sustain Its Market Momentum?
October 10, 2025 05:36 PM AEDT| By SamAustralia’s AGM season begins with several ASX-listed firms, including (ASX:ABB), expected to reveal upbeat updates. Investors closely track performance shifts across the broader ASX stock market landscape.
Prescient Therapeutics Advances PTX-100 to Phase 2, Boosts Funds
October 10, 2025 05:18 PM AEDT| By SamPrescient Therapeutics (ASX:PTX) strengthens its cash position and advances PTX-100 into Phase 2, with global trial expansion and EMA review underway.
CSL (ASX:CSL) Insights: Why Investors Are Watching Closely
October 10, 2025 12:03 PM AEDT| By SamA detailed exploration of CSL (ASX:CSL), its business units, stable healthcare revenue, ethical investing appeal, and insights for the ASX stock market.
Orthocell (ASX:OCC) Achieves 6th Consecutive Revenue Record
October 10, 2025 11:21 AM AEDT| By SamOrthocell (ASX:OCC) achieves a sixth consecutive quarterly revenue record with Remplir’s growth in Australia, Singapore, and the US, driven by strategic expansion and clinical validation.
Race Oncology Advances Cancer Research with G-Quadruplex Expertise
October 09, 2025 02:23 PM AEDT| By SamRace Oncology (ASX:RAC) strengthens its drug development strategy by appointing a G4-DNA pioneer to its advisory board and confirming its lead drug’s anticancer mechanism.
Sonic Healthcare (ASX:SHL): Key Insights in Healthcare Sector
October 08, 2025 12:52 PM AEDT| By SamThis article provides a comprehensive analysis of Sonic Healthcare (ASX:SHL), exploring its global operations, healthcare services, market position, and growth potential within the ASX stock market.
Race Oncology (ASX:RAC) Unveils Novel (E,E)-Bisantrene Pathway
October 06, 2025 04:10 PM AEDT| By SamRace Oncology (ASX:RAC) hosts a webinar to discuss the groundbreaking mechanism of (E,E)-bisantrene, highlighting its role in cancer therapeutics and future clinical strategies.
Unlocking CSL Share Insights: Key Metrics and Market Dynamics
October 06, 2025 03:26 PM AEDT| By SamExplore CSL Ltd (ASX:CSL) share performance, financial health, and market dynamics with insights into revenue, profit, and key business units.
Race Oncology (ASX:RAC) Advances Breakthrough Cancer Therapy
October 03, 2025 02:14 PM AEST| By SamThis article explores Race Oncology Ltd's (ASX:RAC) recent discovery of a novel mechanism of action for its lead drug candidate, (E,E)-bisantrene, highlighting its potential impact on cancer treatment strategies.
Artrya Limited’s New ASX Securities Quotation Sparks Market Focus
October 03, 2025 02:14 PM AEST| By SamArtrya Limited (ASX:AYA) has announced the quotation of new securities on the ASX, highlighting its role in advancing cardiovascular diagnostics and strengthening innovation within the broader Australian stock market.
Exploring ASX 200 Penny Stocks: EZZ Life Science Holdings and Key Market Movers
October 03, 2025 02:05 PM AEST| By SamAustralia’s penny stocks spotlight resilience and growth, featuring EZZ Life Science Holdings, Alfabs Australia, and Dusk Group. These companies showcase diverse opportunities across health, retail, engineering, and resources in the ASX market.
Paradigm Biopharmaceuticals Sparks Investor Curiosity in ASX 200
October 01, 2025 02:01 PM AEST| By SamParadigm Biopharmaceuticals (ASX:PAR) advances Phase 3 trials for osteoarthritis treatment, highlighting biotechnology innovation and potential growth opportunities within the ASX stock market beyond traditional mining and industrial sectors.
EVE Health Launches Dyspro for Patients, ASX 200 Spotlight
October 01, 2025 11:17 AM AEST| By SamEVE Health (ASX:EVE) launches Dyspro prescriptions in Australia and introduces Reclaim My Cycle, enhancing patient support and clinical adoption in women’s health.
Advertise your brand on Kalkine Media